Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.43 |
| ▸ | ESR1 | P03372 | 15/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793852 | 0.85 | ESR2 (0.38) | ESR2ESR1OPRM1OPRD1OPRK1 | |
| SCHEMBL7074686 | 0.76 | ESR2 (0.38) | ESR2ESR1OPRM1OPRD1OPRK1 | |
| SCHEMBL9355063 | 0.72 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL26135697 | 0.65 | TYR (0.42) | ESR2ESR1OPRM1OPRD1OPRK1 | |
| SCHEMBL6796424 | 0.65 | SHBG (0.40) | ESR2ESR1 | |
| SCHEMBL6799659 | 0.64 | DRD2 (0.45) | ESR2ESR1OPRK1 | |
| SCHEMBL9436246 | 0.64 | ESR2 (0.45) | ESR2ESR1STS | |
| SCHEMBL7072760 | 0.63 | OPRM1 (0.33) | ESR2ESR1STSOPRM1OPRD1 | |
| SCHEMBL10899063 | 0.63 | CNR2 (0.46) | ESR2ESR1OPRM1OPRD1OPRK1 | |
| SCHEMBL27526924 | 0.62 | AKT1 (0.41) | ESR2ESR1STSOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ESR2 5/4885ESR1 19/4885STS 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.